Showing results (41-50 of 391) with videos related to
Sort By:
Pageof 40
Plos One|April 25, 2012
Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?Mark I Talan, Ismayil Ahmet, Edward G LakattaProceedings. American Statistical Association. Annual Meeting|September 20, 2023
Design Issues in Longitudinal StudiesChristopher H Morrell, Veena Shetty, Edward G LakattaGerontology|August 30, 2014
Proinflammation of aging central arteries: a mini-reviewMingyi Wang, Robert E Monticone, Edward G LakattaJournal of Clinical Trials|August 8, 2015
Impaired signaling intrinsic to sinoatrial node pacemaker cells affects heart rate variability during cardiac diseaseYael Yaniv, Alexey E Lyashkov, Edward G LakattaThe Medical Clinics of North America|May 12, 2009
Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levelsEdward G Lakatta, Mingyi Wang, Samer S NajjarCurrent Opinion in Nephrology and Hypertension|December 31, 2009
Arterial aging: a journey into subclinical arterial diseaseMingyi Wang, Robert E Monticone, Edward G LakattaCurrent Vascular Pharmacology|January 26, 2012
Milk fat globule epidermal growth factor VIII signaling in arterial wall remodelingMingyi Wang, Hejia H Wang, Edward G LakattaBiology Open|December 6, 2012
Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective propertiesIsmayil Ahmet, Edward G Lakatta, Mark I TalanHeart Failure Reviews|April 4, 2006
Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathyIsmayil Ahmet, Edward G Lakatta, Mark I TalanPhysiology (Bethesda, Md.)|March 5, 2013
Modern concepts concerning the origin of the heartbeatOliver Monfredi, Victor A Maltsev, Edward G LakattaPageof 40